ALTEOGEN Inc - Asset Resilience Ratio

Latest as of March 2026: 55.57%

ALTEOGEN Inc (196170) has an Asset Resilience Ratio of 55.57% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩405.35 Billion
≈ $274.70 Million USD Cash + Short-term Investments

Total Assets

₩729.47 Billion
≈ $494.35 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how ALTEOGEN Inc's Asset Resilience Ratio has changed over time. Check asset allocation strategy of ALTEOGEN Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down ALTEOGEN Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 196170 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩405.35 Billion 55.57%
Total Liquid Assets ₩405.35 Billion 55.57%

Asset Resilience Insights

  • Very High Liquidity: ALTEOGEN Inc maintains exceptional liquid asset reserves at 55.57% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

ALTEOGEN Inc Industry Peers by Asset Resilience Ratio

Compare ALTEOGEN Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Samsung Biologics Co Ltd
KO:207940
Biotechnology 5.66%
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.11%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Immunitybio Inc
NASDAQ:IBRX
Biotechnology 38.07%
89bio Inc
NASDAQ:ETNB
Biotechnology 71.60%
Jinyu Bio-Technology Co Ltd
SHG:600201
Biotechnology 1.20%
Alpha Tau Medical Ltd
NASDAQ:DRTS
Biotechnology 65.79%
Clarity Pharmaceuticals Ltd
AU:CU6
Biotechnology 73.99%

Annual Asset Resilience Ratio for ALTEOGEN Inc (2014–2025)

The table below shows the annual Asset Resilience Ratio data for ALTEOGEN Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 52.04% ₩363.64 Billion
≈ $246.43 Million
₩698.74 Billion
≈ $473.53 Million
+6.75pp
2024-12-31 45.29% ₩185.25 Billion
≈ $125.54 Million
₩409.01 Billion
≈ $277.18 Million
+2.10pp
2023-12-31 43.19% ₩110.61 Billion
≈ $74.96 Million
₩256.10 Billion
≈ $173.56 Million
-8.76pp
2022-12-31 51.95% ₩127.54 Billion
≈ $86.43 Million
₩245.49 Billion
≈ $166.37 Million
-25.64pp
2021-12-31 77.59% ₩202.00 Billion
≈ $136.90 Million
₩260.34 Billion
≈ $176.43 Million
-6.36pp
2020-12-31 83.95% ₩133.66 Billion
≈ $90.58 Million
₩159.21 Billion
≈ $107.89 Million
+11.87pp
2019-12-31 72.08% ₩61.98 Billion
≈ $42.00 Million
₩85.98 Billion
≈ $58.27 Million
-0.09pp
2018-12-31 72.17% ₩51.52 Billion
≈ $34.91 Million
₩71.38 Billion
≈ $48.37 Million
-3.23pp
2017-12-31 75.40% ₩32.43 Billion
≈ $21.98 Million
₩43.01 Billion
≈ $29.15 Million
-2.43pp
2016-12-31 77.82% ₩37.32 Billion
≈ $25.29 Million
₩47.95 Billion
≈ $32.49 Million
+29.84pp
2015-12-31 47.99% ₩18.90 Billion
≈ $12.81 Million
₩39.39 Billion
≈ $26.69 Million
+9.39pp
2014-12-31 38.60% ₩14.65 Billion
≈ $9.93 Million
₩37.96 Billion
≈ $25.72 Million
--
pp = percentage points

About ALTEOGEN Inc

KQ:196170 Korea Biotechnology
Market Cap
$10.13 Billion
₩14.95 Trillion KRW
Market Cap Rank
#2180 Global
#45 in Korea
Share Price
₩279500.00
Change (1 day)
-1.06%
52-Week Range
₩268000.00 - ₩559000.00
All Time High
₩559000.00
About

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more